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  28 
Abstract 29 
Objective: To evaluate the effectiveness of behavioural activation interventions for 30 
people with neurological conditions with co-morbid depression, and explore content and 31 
adaptations.  32 
Data sources: PsycINFO, MEDLINE, CINAHL, AMED, and EMBASE databases 33 
were searched on the 19/11/19. Reference lists of selected full-texts were screened by title.  34 
Review methods: We included peer-reviewed studies, published in English that used 35 
behavioural activation for treatment of depression in adults with a neurological condition. 36 
Single case reports, reviews, and grey literature were excluded. Methodological quality was 37 
assessed by two authors independently and quality was appraised using Critical Appraisal 38 
Skills Programme checklists. 39 
Results: From 2714 citations, 10 articles were included comprising 590 participants. 40 
Behavioural activation was used to treat depression in people with dementia (n=4), stroke 41 
(n=3), epilepsy (n=1), Parkinson’s disease (n=1), and brain injury (n=1). Sample size ranged 42 
from 4 to 105 participants. There were seven randomised-controlled studies, however, no 43 
studies compared behavioural activation to an alternative psychological therapy. The effect 44 
sizes varied between small and large in the studies where effect size could be calculated 45 
(d= 0.24-1.7). Methodological quality of the included studies was variable. Intervention 46 
components were: identifying and engaging in pleasurable activities, psychoeducation, and 47 
problem solving. Adaptions included: delivering sessions via telephone, delivering 48 
interventions via primary caregivers, and giving psychoeducation to caregivers.  49 
  Conclusion: The effectiveness of behavioural activation in randomised-controlled 50 
trials varied from small to large (d= 0.24-1.7) in reducing depression. The content of 51 
behavioural activation was comparable to established treatment manuals. Adaptations 52 
appeared to support individuals to engage in therapy.  53 
 54 
Review registration: PROSPERO 2018, CRD42018102604. 55 
Key words: Neurological conditions, depression, behavioural activation, behavioural therapy, 56 
activity scheduling 57 
  58 
Behavioural activation treatment for depression in individuals with neurological 59 
conditions: A systematic review 60 
 61 
Introduction 62 
People with neurological conditions experience higher rates of depression than those 63 
in other patient groups without neurological conditions 1. Decreased social activities 64 
contribute to the continuation and exacerbation of depression through a loss of contact with 65 
contingencies that were previously reinforcing and mood enhancing 2. Conversely, 66 
engagement in social and leisure activities for people with multiple sclerosis promotes 67 
positive mood and wellbeing 3, 4. With depression and reduced or declining physical abilities 68 
(common in many neurological conditions), individuals find it difficult to identify with and 69 
engage in activities that have pleasurable or reinforcing consequences 2. 70 
In the UK, National Institute of Health and Clinical Excellence recommends the use 71 
of cognitive behavioural therapy for treating depression in individuals with chronic physical 72 
health problems (including neurological conditions) 5. However, cognitive-behavioural 73 
therapy is not best suited for people with neurological conditions 6, because many have 74 
cognitive difficulties that may make accessing and engaging with cognitive-behavioural 75 
therapy difficult 7. Therefore, adapting psychological therapies to better consider the 76 
interaction of co-morbid psychological and physical conditions may be more acceptable to 77 
people with neurological/physical health conditions 8.  78 
Behavioural activation is a type of psychological therapy that encourages individuals 79 
with depression to engage in activities they have been avoiding. Individuals define goals and 80 
activity schedules 9. Behavioural activation is a relatively simple, easy to understand, 81 
intervention that does not require a highly trained therapist or complex skills from the patient 82 
10, and may be suitable for individuals with cognitive and physical difficulties. 83 
In non-neurological populations, the behavioural activation component of cognitive-84 
behavioural therapy is as effective alone compared to when used in combination with 85 
cognitive aspects 11 – and has been found to be as effective as antidepressant medication 12. A 86 
meta-analysis of activity scheduling (a type of behavioural activation) interventions for the 87 
treatment of depression found a pooled effect size (d) of 0.87, favouring activity scheduling 88 
over waitlist or placebo controls or alternative psychological therapies (95% CI: 0.60~1.15) 89 
13. Behavioural activation is also considered cost-effective for depression 14. However, the 90 
evidence for the effectiveness of behavioural activation in people with neurological 91 
conditions is inconclusive.  92 
Therefore, this review aimed to: (i) report the evidence of the effectiveness of 93 
behavioural activation interventions for individuals with neurological conditions with co-94 
morbid depression, with outcomes of interest being mood, function, activity, and quality of 95 
life; (ii) describe the content of behavioural activation interventions; and (iii) identify the 96 
adaptations made to the behavioural activation intervention specifically for people with 97 
neurological conditions.  98 
 99 
Method 100 
 101 
We followed the PRISMA-P 2015 guidelines 15 and the protocol was prospectively registered 102 
on PROSPERO (CRD42018102604). 103 
 104 
The following online databases were searched: Medline (1970-present), CINAHL 105 
(1970-present), PsycINFO (1970-present), EMBASE (1980-present), and AMED (1980-106 
present). The last search was completed on 19/11/2019. The following keywords were used: 107 
Behavioural activation, behaviour therapy, activity scheduling, depression, and neurological 108 
conditions. We used variations of these terms including medical subject headings (MeSH) 109 
where available. For a complete list of the search terms please refer to Appendix A. Terms 110 
were ‘exploded’ and used singularly or in conjunction with similar terms based on the 111 
database being searched. The reference lists of the selected full-texts were screened by title, 112 
as an additional way of identifying relevant articles.  113 
 114 
Included studies were: Peer-reviewed, quantitative or qualitative, and published in 115 
English. Studies were required to include: (a) behavioural activation for treatment of 116 
depression (clinician confirmed diagnosis or scoring above defined thresholds on validated 117 
depression measures); (b) adults (≥16 years) with a neurological condition, defined as a 118 
condition or disease of the brain, as a result of illness or injury. Studies using behavioural 119 
therapy were included where the use of activity scheduling and monitoring was of primary 120 
focus; which was defined as the targeting of behavioural avoidance and increasing contact 121 
with environmental positive reinforcement. We were primarily interested in clinical 122 
effectiveness of the intervention on the patient, but we also included outcomes that related to 123 
the care-giver. We excluded articles that were policy papers, books, theses, or conference 124 
proceedings.  125 
 126 
Data extraction was completed by the first author and accuracy was checked by the 127 
other authors. Table 1 summarises the data extracted. Following the database searches, results 128 
were transferred to Microsoft Excel and duplicates were removed. The first author screened 129 
titles and abstracts, before reviewing full text articles. Data extraction was completed using a 130 
predefined template informed by the reader's guide to critical appraisal of cohort studies 16-18 131 
(for the template headings please see Appendix B).  132 
 133 
Following PRISMA guidance 16-18, the first and one other author independently 134 
assessed the methodological quality of each included article. Discrepancies were resolved 135 
through discussion. The quality appraisal framework selected was informed by the study 136 
design of the included articles: Critical Appraisal Skills Programme Randomised Controlled 137 
Trials checklist 19, cohort studies checklist 20, qualitative checklist 21, and Mixed Methods 138 
Appraisal Tool– Version 2011 22. 139 
 140 
A narrative summary for data analysis was conducted due to the low number of 141 
articles identified. A meta-analysis was not considered because we only had a small number 142 
of studies, with considerable heterogeneity in terms of study designs, outcome measures, and 143 
measurement time-points. Therefore, to compare and synthesise effectiveness data, effect size 144 
estimates were used (with effect size determined from study data when not reported). Where 145 
multiple depression measures were used the primary measure was used. Through conversion 146 
into standardised between-condition effect-sizes, we treat studies as comparable with respect 147 
to the comparison condition (e.g., that usual care is similar across studies); however, if 148 
comparators (e.g., forms of ‘usual care’) differ systematically across studies, then this 149 
assumption (of transitivity) would be violated: the treatment effect will not be defined 150 
independently of individual comparators (i.e., there will be a treatment-by-study interaction). 151 
  152 
Results 153 
 154 
Initial database searches identified 2714 articles, 49 full text articles were considered 155 
for inclusion, and 10 articles (with 590 participants) met our inclusion criteria. Figure 1 is the 156 
PRISMA flow diagram.  157 
 158 
[Figure 1 about here] 159 
 160 
All included articles were quantitative intervention studies: seven randomised-161 
controlled trials 23-29, one cohort study 30, and two multiple baseline experimental design 162 
studies 31, 32.  The articles were published between 1991 and 2019, based on studies from the 163 
USA 23, 26-32, UK 24 and Australia 25. The components and format of the behavioural 164 
activation interventions are summarised in Table 1, which also describes the clinical context 165 
of each intervention, and the comparator groups (where used). 166 
 167 
[Table 1 about here] 168 
 169 
The quality of the studies, as seen in Table 2, was variable. All had a clearly stated 170 
aim and identified their target sample. Participant demographics were adequately detailed in 171 
almost all studies, but one 32. Studies and sample representativeness varied from low to high. 172 
Sample sizes ranged from 4 to 105 participants 24, 32.  173 
The quality of reporting of the studies also varied. In randomised-controlled trials the 174 
method of randomisation was reported in all but one study 23, with most studies using 175 
computer generated algorithms 24-30, 32. In five randomised-controlled trials assessors were 176 
blinded to participant group allocation 23, 26-29; in one study assessors were only blinded to 177 
secondary measures 24; and in one study there was no blinding of data collection 25. Only two 178 
studies reported data on treatment fidelity 24, 30, with most studies collecting no or minimal 179 
data on the delivery of the intervention 23, 25-29, 31, 32. All studies included or described data 180 
pertaining to the validity and reliability of assessment measures.  181 
Additional sources of possible methodological biases were evident, such as reporting 182 
bias (not detailing all outcomes) 27, use of self-report methods to assess depression 23-28, 30-32, 183 
and caregivers completing depression assessments on the participants’ behalf 23, 31, 32. One 184 
study 31 used a single-case experimental design but did not report any statistical analysis or 185 
present any data for depression. One study 32 used a single-case experimental design but did 186 
not consistently establish a baseline before introducing the intervention, as recommended by 187 
multiple single case experimental design standards 33.  188 
 189 
[Table 2 about here] 190 
 191 
Variants of behavioural activation processes, such as activity scheduling or 192 
monitoring were used in samples with dementia 23, 25, 31, 32, stroke 24, 27, 28, epilepsy 26, 193 
Parkinson’s disease 30, and brain injury 29. Participants were recruited from nursing homes, 194 
hospital clinics and the community. The mean age range was 38.5 to 86.5 years. A number of 195 
studies recruited patient-caregiver dyads and investigated the effects of using paid and unpaid 196 
caregivers as intervention aids 23, 25, 31, 32. Additionally, studies reported the impact of 197 
behavioural activation for patients, on caregivers’ depression, quality of life, and/or perceived 198 
burden 23, 30, 32.  199 
The following assessments were used to assess depression outcomes: The Cornell 200 
Scale for Depression in dementia 34 [23, 31], The Hamilton Depression Rating Scale 35 [23, 27, 28, 201 
32], Stroke aphasic depression questionnaire 21-item hospital version 36 [24], Geriatric 202 
Depression Scale-12 37 [25, 27, 28, 30], The Patient Health Questionnaire 38 [29], and the Hopkins 203 
Symptom Checklist – 20 39 [26]. Caregiver depression was consistently assessed using The 204 
Hamilton Depression Rating Scale 35 [23, 32].  205 
Seven studies used comparator groups; six used a two-arm design, of which, four used 206 
usual care for one arm 24, 26-28, one used a walking and talking intervention as a comparison 207 
group 25, and one used a motivation intervention 29. Another study 23 had four arms 208 
(behavioural therapy and pleasant events, behavioural therapy and problem-solving, usual 209 
care, and waitlist control). Attrition rates were reported for all studies and ranged from 5% 25 210 
to 27% 31.  211 
 212 
In terms of effectiveness (aim i) eight of ten studies reported a positive outcome for 213 
behavioural activation in terms of improving depressive symptoms 23, 24, 26, 28-32. In studies 214 
reporting effects favouring the intervention, estimable effect size ranged from d = 0.38–1.7 215 
(for parity, where multiple follow-up assessments were reported, the first post-intervention 216 
effect-estimate was selected). When the lowest quality studies were not considered (i.e., 217 
limiting to 23, 24, 26, 28) the effect size range remained the same. 218 
Conversely, two studies did not favour behavioural activation, reporting non-219 
superiority for reducing depression relative to usual care (d at first [8-week] follow-up = 220 
0.24, p = 0.30) 27 or a walking-and-talking intervention (d not reported, p = 0.61) 25. 221 
Overall, across the six studies for which effect-sizes were estimable 23, 24, 26, 27, 28, 30  , 222 
effects of behavioural activation ranged widely at first follow-up (post-intervention): from 223 
small-to-large magnitude (ds = 0.24–1.7). The same range (ds = 0.24–1.7) was observed 224 
when limiting to the five studies that estimated effect-size against a comparator 23, 24, 26, 27, 28; 225 
all these effects were estimated relative to a usual care condition, in a randomised-controlled 226 
trial design, although the nature of ‘usual care’ likely differs across populations and between 227 
individual studies. 228 
Considering findings by population, there was at least one favourable finding for each 229 
study population. Behavioural activation treatment was favoured in three of four dementia-230 
focussed studies (observed ds 0.9–1.7 [at first follow-up]) and two of three stroke-focussed 231 
studies (largest observed ds 0.24–1.17), with favourable findings in each of the (single) 232 
studies examining effects for patients with epilepsy (d = 0.38), Parkinson’s disease (d = 233 
0.70), and brain injury (d unreported). 234 
In terms of effect-sizes at longer-term follow-ups, four randomised-controlled trials 24, 235 
26, 27, 28 provided estimates of effect-size (comparing behavioural activation with usual care) at 236 
5–6 months: these ranged from negligible (0.05 27) to moderate (0.77 24) magnitude. Of the 237 
four randomised-controlled trials, three further provided estimates of effect-size at 12 238 
months, and these again ranged from negligible (0.10 27) to moderate (0.70 26) magnitude. 239 
Further to effects on patient outcomes, there were reported benefits of patient-focused 240 
behavioural activation on caregivers’ depression in two studies 23, 32 (reduced caregiver 241 
depression on the Hamilton Depression Rating Scale). Another study 24 found no significant 242 
effects of patient-focussed behavioural activation on caregiver strain or leisure activities – 243 
although caregivers expressed high satisfaction with the care provided. 244 
In terms of content (aim ii), behavioural activation interventions included the use of 245 
psychoeducation, identifying pleasurable activities, scheduling pleasant activities, graded task 246 
assignments, and problem-solving. The interventions were delivered by study therapists, care 247 
home staff, master’s degree students, and unpaid caregivers. In one study, behavioural 248 
activation was delivered in two formats (face-to-face and telephone) and was compared to 249 
usual care 27, however, due to low recruitment numbers and being under-powered the 250 
interventions arms were combined and compared to usual care. Across studies, the number of 251 
sessions delivered ranged from one 29 to twenty 24, with most studies delivering between six  252 
and nine sessions 23-28, 30, 32. Where reported, the duration of sessions ranged from 10 minutes 253 
27, 30 to one hour 23, 24, 32. The duration of the intervention in most studies was one hour. One 254 
study used a single session followed by eight weeks of daily text messages 29.   255 
 256 
With respect to aim (iii), few adaptations were made to the content of the delivered 257 
behavioural activation intervention. Where adaptations were made, the most frequent 258 
addition to the programme was problem-solving 25-28. In one study the problem-solving 259 
content was focused on the behavioural challenges, presented by patients with dementia, 260 
whereas one study used problem-solving to support access to pleasant activities 25.  261 
Carers were involved in four studies. For instance, psychoeducation was delivered to 262 
the caregiver rather than the patient 23, 32, or caregivers (paid and unpaid) assisted in the 263 
delivery of behavioural activation 23, 25, 31, 32 or to support access to pleasant activities 25, 31. 264 
Where caregivers were used to deliver behavioural activation, reduction in low mood for 265 
patients was shown in two studies23, 32, but mixed results were found in relation to reduction 266 
in patient depression when paid caregivers supported access to pleasant activities.  267 
Finally, the method of delivery in all studies was one-to-one, and no group studies 268 
were identified. In one study 32 both the caregivers and patient attended sessions, with the 269 
first three sessions attended by both parties, and the remaining five sessions only the 270 
caregivers attended. In all but two studies26, 30, sessions were delivered face-to-face. 271 
However, one study used a single face-to-face session followed by a series of text messages; 272 
the content of the messages having been agreed during the initial session 29. In one study 27, 273 
one treatment arm received telephone contact, however, the results were combined with the 274 
face-to-face arm and compared to usual care.   275 
 276 
Discussion 277 
 Overall, we found some indication that behavioural activation is effective in the treatment of 278 
depression in individuals with neurological conditions with effects maintained beyond a six-279 
month period. Behavioural activation had a varied effect between small and large in the 280 
studies where effect size could be calculated (d= 0.24-1.7, in six of seven randomised-281 
controlled trials) in reducing depression. The largest effect size includes the combined 282 
reporting of the intervention arms of behavioural therapy pleasant events and behavioural 283 
therapy problem solving 23, when excluding the combined intervention arms the same varied 284 
range of small to large effect sizes were observed across included articles.  This finding is 285 
consistent with a previous meta-analysis, which concluded that behavioural activation for 286 
depression in individuals without a neurological condition is effective (d = 0.87)13. In our 287 
review, participants with Parkinson’s disease or epilepsy benefitted the most on depression, 288 
quality of life, and apathy outcomes. In studies with dementia or stroke samples, varying 289 
levels of effectiveness were found. However, these results should be treated with caution, 290 
because the quality of some studies was not optimal.  291 
Most studies reported statistically significant differences in the reduction of 292 
depression, but effect sizes were not reported in all cases. The variance in the reported 293 
outcomes may be a result of the design and delivery of the intervention, clinical condition, 294 
outcome measures, timing of assessments, and comparators (or lack thereof). The good 295 
quality studies suggested that behavioural activation was clinically and cost effective, and 296 
they were reported in a way that would enable replication. The findings from the other 297 
studies, however, must be treated with caution because depression was not always the 298 
primary presenting difficulty. Furthermore, studies had small sample sizes. Only five of ten 299 
studies conducted a sample size calculation or power analysis 24, 26-28, 30, and three studies did 300 
not reach their recruitment target 24, 26, 27.  301 
Half of the trials included follow-ups of six-months or longer 23, 24, 26-28. This is 302 
beneficial as it provides an insight into continued benefits of the intervention. All but one 27 - 303 
which had no significant benefits in depression outcomes at the end of treatment - reported 304 
significant continued benefits at long-term follow-up.  305 
Few studies reported making any adaptations to the intervention specifically for the 306 
populations studied. Where adaptations were mentioned, these included adding a problem-307 
solving component to the behavioural activation intervention, delivering sessions by 308 
telephone, and teaching caregivers (paid and unpaid) to facilitate behavioural activation and 309 
provide access to pleasurable activities.  310 
One study added a problem-solving component to standard behavioural activation, but 311 
it was unclear whether this additional component was specific to overcoming barriers to 312 
activities or providing support for individuals’ difficulties in day-to-day tasks. A more 313 
generic problem-solving approach may have introduced a deviation from behavioural therapy 314 
interventions. A lack of fidelity assessment and assessment of participant adherence makes it 315 
difficult to determine what the participants actually received in terms of ‘content’ and the 316 
‘dose’ of the intervention. Where reported, the average number of pleasant activities 317 
completed increased significantly (p< 0.005) from baseline, and a significant positive 318 
relationship between depressed mood and duration and frequency of pleasant events was 319 
identified (mean = 0.72, SD = 0.16, t(3) = 2.07, p<0.08).  320 
In terms of intervention delivery format, we were not able to determine the relative 321 
effectiveness of telephone versus face-to-face delivery, as only one study made this 322 
comparison, and the outcomes did not differ significantly from each other, however, data 323 
were not presented detailing the comparison. Two studies reported a medium effect size in 324 
the reduction of depression using a combination of face-to-face and telephone (d=0.70), 325 
which suggests that telephone as a mode of delivery may be of benefit to individuals, 326 
particularly because some may experience physical difficulties and may struggle to attend 327 
appointments. Behavioural activation sessions varied in number and length of sessions. In 328 
clinical settings the variability may support clinicians and services with limited resources. 329 
However, more research is needed to investigate the effectiveness of behavioural activation 330 
in fewer sessions.    331 
Using unpaid caregivers to support the delivery of behavioural activation may be a 332 
benefit to both the person with a neurological condition and the caregiver themselves. 333 
Caregivers experienced a reduction in depression, but behavioural activation had no impact 334 
on perceived strain/burden. This may be because the person they care for continues to have 335 
care needs, with or without the presence of depression, which the caregiver continues to 336 
facilitate. Indeed, high care need is associated with higher levels of caregiver strain and 337 
poorer quality of life 40.  338 
 339 
One strength of this review is that the search strategy was tested, and the search terms 340 
were refined with a specialist study librarian before the final search, which increased the 341 
likelihood of identifying papers. The electronic search and hand search of full-text reference 342 
lists increases confidence that most relevant research was included in this systematic review 343 
and that the conclusions made in the review are based on a synthesis of available evidence.  344 
Our findings, however, must be viewed in light of the review’s limitations. We could 345 
only find a small number of studies to include, and many of the studies had small sample 346 
sizes, and considered few neurological conditions. None of the studies compared behavioural 347 
activation with another psychological or pharmacological intervention, therefore no direct 348 
comparisons of effectiveness were possible. Only peer-reviewed literature was included and 349 
as a result the exclusion of unpublished findings may bias the results to demonstrate a 350 
positive effect of the intervention. This exclusion criterion was applied to ensure that only 351 
methodological robust studies were included. When considering the potential of publication 352 
bias, future reviews might benefit from including grey-literature. Finally, only one author 353 
screened articles for inclusion. 354 
Future research should consider and address methodological and conceptual 355 
limitations of published studies as highlighted in this review. For example, data should be 356 
reported for each arm of randomised-controlled trials. Studies should assess the fidelity of the 357 
delivery of the behavioural activation intervention, and activity participation should be 358 
recorded as an outcome to determine whether changes are directly related to behavioural 359 
activation. A fully powered randomised-controlled trial with longer-term follow-ups, and 360 
head-to-head comparisons with alternative psychological therapies, with an evaluation of the 361 
cost-effectiveness, to determine which is most effective intervention is warranted.  362 
 363 
Clinical messages 364 
 There is some evidence that behavioural activation is beneficial in reducing 365 
depressive symptoms in several neurological conditions, although the low quality of 366 
studies means the findings should be interpreted with caution. 367 
 Behavioural activation interventions have been delivered in a number of formats such 368 
as telephone, face-to-face, and carer supported, with varying number and length of 369 
sessions. 370 
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Table 1 503 
Summary of the extracted data 504 
Study number, 
author(s), date, 
and country  
31 Feliciano, Steers, 
Elite-
Marcandonatou, 
McLane, & Areán 
(2009), USA 
23 Teri, Logsdon, 
Uomoto, & 
McCurry (1997), 
USA 
25 Travers 
(2017), 
Australia 
32 Teri and 
Uomoto (1991), 
USA 
24 Thomas, Walker, 
Macniven, 
Haworth, & 
Lincoln (2013), UK 
27 Kirkness, Cain 
et al. (2017), USA 
28 Mitchell, 
Veith, et al. 
(2009), 
USA 
26 
Ciechanowski, 
Chaytor et al. 
(2010), USA 
30 Butterfield, 
Cimino, et al. 
(2017), USA 
29 Hart, Vaccaro, 
Collier, Chervoneva 
& Fann (2019), 
USA 
Method, 
recruitment, & 
depression 
identification 
method 
Single case 
experimental 
design. Pre-post- 
test. Non-concurrent 
multiple baseline 
design. Community: 
CSDD 
RCT. Community: 
Caregiver report, 
Clinical interview, 
CSDD, HDRS 
Pilot RCT. 
Interview 
with care 
staff. 
Community: 
GDS 
Single case 
experimental 
design. Pre-post- 
test (n=2), AB 
(n=1), ABAB 
(n=1). 
Community: 
DSM-III criteria, 
HDRS 
RCT. Community: 
SADQH-10, 
PSADQH-21 
RCT. 
Community: 
Screen: GDS ≥11; 
Study start: 
Clinical interview, 
DSM-IV criteria, 
HDRS 
RCT. 
Community: 
Screen: 
GDS ≥11; 
Study start: 
Clinical 
interview, 
DSM-IV 
criteria, 
HDRS 
RCT. 
Community: 
PHQ-9 
Experimental 
design. Pre- 
/post- test. 
Community: 
GDS 
RCT.  NR.  Patient 
Health 
Questionnaire-9  
Sample 
characteristics  
Population: 
Dementia 
Total: n=11 
Age (Years): Range 
=78-95, M=85.6 
Female gender: 
n=10 (91%) 
Intervention: 
Masters-level 
clinicians n=2 
Population: 
Dementia 
Total: n=72 
participant-
caregiver dyads; 
BT-PE n=23; BT-
PS n=19; Usual care 
n=10; Wait list 
control n=20 
Age (Years): Range 
= not reported, 
M=76.4 (SD=8.2); 
BT-PE M=72.8 
(SD=8.2); BT-PS M 
=78.5 (SD=7.9); 
Usual care M=79.5 
(SD=6.9), Wait list 
control M=76.8 
(SD=8.2); Caregiver 
M=66.9 (SD=11.0) 
Female gender: 
n=34 (47%); BT-PE 
n=16 (70%); BT-PS 
n=5 (26%); Usual 
Population: 
Dementia 
Total: 
n=18; BT 
n=10; 
Walking 
and talking 
n=8 
Age 
(Years): 
Range = not 
reported, 
M=86.5 
(SD=8.8); 
BT M=87.2 
(SD=7.7); 
Walking 
and talking 
M=85.5 
(SD=10.9) 
Female 
gender: 
n=16 (89%); 
BT n=8 
Population: 
Dementia 
Total: n=4 
patient caregiver 
dyads 
Age (Years): 
Range=74-81, 
M=78 
(SD=3.16); 
Caregiver 
range=32-47, 
M=38.5 
(SD=7.23) 
Female gender: 
n=2 (50%); 
Caregiver n=2 
(50%) 
Intervention: 
Psychologist 
(n=1); Caregiver 
(n=4) 
Population: Stroke 
with aphasia 
Total: n=105; BT 
n=51; Usual care 
n=54 
Age (Years): 
Range=29-94, 
M=67.0 (SD=13.5); 
BT M=68.5 
(SD=13.1); Usual 
care M=65.5 
(SD=13.9) 
Female gender: 
n=39 (37%); BT 
n=22 (43%);  
Usual care n=17 
(31%) 
Intervention: 
Assistant 
psychologists (n=8) 
Population: 
Stroke 
Total: n=100; 
Intervention 
telephone n=37; 
Intervention face-
to-face n=35; 
Usual care n=28 
Age (Years): 
Range=23-88, 
M=NR; 
Intervention 
telephone =31-85, 
M=61.7;  
Intervention face-
to-face =23-83, 
M=58.5 
(SD=NR); Usual 
care =32-88, M = 
60.7 (SD = NR) 
Female gender: 
n=50 (50%); 
Intervention 
telephone n=18 
Population: 
Stroke 
Total: 
n=101; 
Intervention 
n=48; Usual 
care n=53  
Age 
(Years): 
Range 25-
89, M=NR; 
Intervention 
=25-88, 
M=57 
(SD=NR); 
Usual care 
=29-88, 
M=57 
(SD=NR) 
Female 
gender: 
n=40 (40%); 
Intervention 
n=19 (40%); 
Population: 
Epilepsy 
Total: n=80; 
BT n=40; Usual 
care n=40 
Age (Years): 
Range=NR, 
M=43.9 
(SD=11.0); BT 
M=43.4 
(SD=11.0); 
Usual care 
M=44.4 
(SD=11.1) 
Female gender: 
n=42 (53%); BT 
n=19 (48%); 
Usual care n=23 
(58%)  
Intervention: 
Social workers 
n=3 
Population: 
Parkinson's 
disease 
Total: n=34 (27 
analysed). n=27 
spouse/family 
members 
Age (Years): 
Range=44-86, 
M=66 
(SD=10.7) 
Female gender: 
n=5 (19%) 
Intervention: 
Principle 
investigator 
(n=1), students 
(n=3) 
Population: Brain 
Injury 
Total: n= 65; BA 
intervention n=43, 
Motivation 
intervention n=22. 
Attrition n=6 (BA 
intervention = 5, 
Motivation 
intervention =1) 
Age (Years): Range 
NR, BA 
intervention M 40.4, 
Motivation 
intervention M 38.5. 
Female gender: 12 
(20.3%). BA 
intervention n=8 
(21%), Motivation 
intervention n=4 
(19%). 
Intervention: 
Researchers 
care n=6 (60%); 
Wait list control 
n=7 (35%); Female 
caregiver n=50 
(69%) 
Intervention: 
Psychologist (n=1) 
(80%); 
Walking 
and talking 
n=8 (100%) 
Interventio
n: Care staff 
(n=NR) 
Interview: 
Staff (n=14) 
(49%); 
Intervention face-
to-face n=18 
(51%); Usual care 
n=14 (50% )  
Intervention: 
Study therapist 
(n=1) 
Usual care 
n=21 (40%)  
Interventio
n: Study 
therapist 
(n=1) 
Intervention 
and format 
Manualised: No 
Components: 
Identifying 
pleasurable 
activities, 
communicating 
activities to 
caregivers, 
Developing 
behaviour plans 
Number and 
length of sessions: 
NR 
Mode of delivery: 
Face-to-face 
Format: Individual 
Comparator: None 
Manualised: Yes 
Components: 
Psychoeducation for 
caregivers, 
Psychoeducation, 
identifying 
activities, Activity 
scheduling, Activity 
monitoring, 
Caregiver problem-
solving, Caregiver 
activity scheduling, 
Working with 
behavioural 
disturbances, 
Relapse prevention 
Number and 
length of sessions: 
9 (1-hr) 
Mode of delivery: 
Face-to face. 
Caregiver supported 
by therapist 
Format: Individual 
Comparator: BT-
PS, Usual care, 
Wait list control 
Manualised
: Yes (BE-
ACTIV) 
Component
s: Involving 
activities 
staff, 3-hr 
staff 
training 
component, 
identifying 
activities, 
Activity 
scheduling, 
increasing 
activities, 
Behavioural 
managemen
t 
Number 
and length 
of sessions: 
8 sessions 
(NR) 
Mode of 
delivery: 
Face-to-face 
Format: 
Individual 
Comparato
r: Walking 
and talking 
Manualised: No  
Components: 
Psychoeducation 
for patients and 
caregivers, 
identifying 
activities, 
Engagement in 
activities, 
Activity tasks 
supported by 
caregivers 
Number and 
length of 
sessions: 8 (1-
hr). Patient 3 of 
8 sessions, 
caregiver 8 of 8 
sessions. 
Mode of 
delivery: Face-
to-face 
Format: 
Individual and 
caregiver 
Comparator: 
None 
Manualised: Yes 
Components: 
Maximising mood-
elevating activities, 
Psychoeducation, 
Activity 
monitoring, 
Activity 
scheduling, 
Grading tasks, 
Communication 
adaptations 
Number and 
length of sessions: 
<20, M=9.07 
(SD=2.36), range 3-
18 (1-hr) 
Mode of delivery: 
Face-to-face 
Format: Individual 
Comparator: 
Usual care 
Manualised: Yes 
Components: 
Psychoeducation, 
Identifying 
activities, Activity 
scheduling, 
Problem-solving, 
Skills review  
Number and 
length of 
sessions: 6 (10-80 
min). Telephone 
intervention 
M=26 min, face-
to-face M=38 min 
Mode of 
delivery: Group 
1, telephone; 
Group 2, face-to-
face 
Format: 
Individual 
Comparator: 
Usual care 
Manualised
: Yes 
Component
s: 
Psychoeduc
ation, 
Identifying 
activities, 
Activity 
scheduling, 
Problem-
solving, 
Skills 
review  
Number 
and length 
of sessions: 
9 (NR) 
Mode of 
delivery: 
Face-to-face 
Format: 
Individual 
Comparato
r: Usual 
care 
Manualised: 
Yes (PEARLS) 
Components: 
Activity 
scheduling, 
Activity 
monitoring, 
Behavioural 
activation, 
Problem-
solving,   
Focus on social 
and physical 
activation 
Number and 
length of 
sessions: 8 (50 
min) 
Mode of 
delivery: Face-
to-face, 
telephone 
Format: 
Individual 
Comparator: 
Usual care 
Manualised: 
Yes (BATD) 
Components: 
Goal setting, 
Activity 
scheduling, 
Activity 
monitoring 
Number and 
length of 
sessions: 6 (2-
2.5-hr, n=1; 10-
20 min. n=5)  
Mode of 
delivery: Face-
to-face (n=1), 
telephone (n=5), 
automated web 
reminders 
Format: 
Individual 
Comparator: 
None 
Manualised: 
Scripted sessions 
Components: 
Psychoeducation, 
identifying 
activities, activity 
scheduling, 
implementation 
intentions 
Number and 
length of sessions: 
Face-to-face (n=1), 
telephone (n=1), 
Text messages 
(n=8) 
Mode of delivery: 
Face-to-face and 
telephone 
Format: Individual 
Comparator:  
Motivation 
interventions 
Measurement 
time points and 
measures. 
Effect size* 
Pre- and post-
Intervention: 
CMAI-Long form, 
MAS, MMSE, 
ADL, CSDD, PES, 
RAISD. 
Effect size: 
NR/insufficient data 
Pre- and post-
Intervention: 
CSDD, HDRS, 
MMSE, DRS, RIL 
Caregiver: HDRS 
Effect size: 
Depression: BT-PE 
& BT-PS effect size 
ranged from d=0.9-
1.7 on the HDRS 
and CSD 
BT-PE BDI d=0.4; 
BT-PS BDI d=1.0  
Caregiver: HDRS 
[F(3,66) 
= 4.73, p < .01] 
6-month follow up 
Significant effects 
on reduced sample 
maintained.  
Pre- and 
post-
Interventio
n: GDS, 
QOL-AD-
nursing 
home, PES-
nursing 
home, 
MMSE.  
Effect size: 
NR/insuffici
ent data 
Pre- and post-
Intervention 
daily:  
HDRS, PES-
elderly version 
(caregiver to 
patient), MMSE, 
Caregiver: 
HDRS 
Effect size: N/A 
3- and 6-months 
post-
randomisation: 
SADQH-10, 
SADQH-21, NLQ, 
CSI, SST, FAST, 
BI, VASES 
Effect size: 
Depression: Three-
month dKorr = 
0.542; Six-month 
dKorr = 0.771 
Baseline, 8-weeks 
(post-
intervention), 21-
weeks, 12-
months:  
HDRS, NIHSS, 
GDS, BI, SIS 
Effect size: 
Depression: 8-
week d= 0.243; 
21-week d= 
0.053; 12-month 
d= 0.104 
Baseline, 9-
weeks 
(post-
interventio
n), 21-
weeks, 12-
months: 
HDRS, 
NIHSS, 
GDS, BI, 
SIS 
Effect size: 
Depression: 
9-week d = 
1.172; 21-
week d= 
0.341; 12-
months d= 
0.484; 24-
month d= 
0.398 
Baseline, 6- 
and 12-
months: HSCL-
20, QOLIE-31 
Effect size: 
Depression: 6-
month d= 0.38; 
12-month d= 
0.704 
Baseline, post-
intervention, 1-
month follow-
up: AES, GDS, 
UPDRS, PDQ-
39 
Caregiver: ZBI 
Effect size: 
Depression: d= 
0.70; Apathy: 
d= 0.77; Quality 
of Life: d= 0.5 
Pre-, mid-, and 
post-intervention: 
EROS, BADS 
Effect size: NR 
Summary 
points and key 
findings 
Only four 
participants were 
depressed - change 
was observed in two 
of the four. 
One participant had 
a clinically 
significant change 
(a 11-point drop) 
and one participant 
had a small decrease 
in score that was not 
clinically 
significant.  
PES was completed 
with eight 
participants (73%) 
the remaining 3 
were completed by 
family members or 
care staff. 
Participants in both 
behavioural groups 
showed significant 
improvement in 
depressive 
symptoms 
compared to those 
in the usual care and 
wait list control. 
Caregiver 
depression 
improved on the 
HDRS.  
25 participants 
(60%; 95% CI = 
[.45, .74]) in the 
active treatment 
conditions showed 
clinically significant 
improvement. 
At six-months 
participants and 
The average 
number of 
activities 
completed 
by the 
intervention 
group 
increased 
from 
baseline (z= 
2.82, p< 
0.005). 
Quality of 
life 
improved in 
the walking 
and talking 
group 
(p=0.04) 
from 
baseline.  
Qualitative 
Significant 
positive 
relationship 
between 
depressed mood 
and duration and 
frequency of 
activities.  
Less depressed 
mood was 
associated with a 
longer duration 
and higher 
frequency of 
activities.  
The duration of 
activities may be 
more important 
to mood than 
frequency of 
activities. 
No baseline data 
Allocation to 
behavioural 
activation 
compared to usual 
care significantly 
predicted better 
self-reported mood, 
self-esteem and 
observer-rated 
mood three months 
after 
randomisation. No 
significant effects 
for behavioural 
activation on 
caregiver strain or 
leisure activities (p 
values not 
reported). Both 
participants and 
caregivers reported 
higher satisfaction 
Intervention 
groups were 
combined and had 
a mean reduction 
on HDRS scores 
of 39% (40% 
face-to-face and 
38% telephone) 
compared to 33% 
reduction in usual 
care at 8 weeks, 
no significant 
difference.  
The modality of 
intervention (face-
to-face and 
telephone) were 
comparable for 
outcomes. 
Mean 
decrease in 
depression 
was 
significantly 
greater at 1-
year 
compared to 
control.  
Intervention 
resulted in 
significantly 
greater 
depressive 
symptom 
reduction over 
12-months 
compared with 
usual care.  
Apathy and 
depression 
scores were 
significantly 
different with a 
large effect size. 
Depression 
scores were 
maintained one 
month follow 
up. 
The difference 
between conditions 
was not significant 
for 8-week changes 
or 4-week changes 
for any outcome 
measure.  
caregivers in active 
treatment conditions 
(BT-PE & BT-PS) 
maintained 
significant 
improvement. 
comments: 
93% of staff 
reported 
benefits for 
the 
intervention 
group. They 
reported 
improved 
mood in 
four 
residents 
and greatly 
reduced 
anxiety in 
one 
resident, 
from 
baseline.  
was collected for 
50% of the 
participants 
Caregiver 
depression: 
Caregivers with 
depression at 
pre-treatment 
(n=2) showed a 
reduction in 
HDRS and BDI 
scores. 
with emotional 
support, 
communication 
support, and 
hospital and 
community 
services. 
Note: * all favoured intervention. NR = Not reported.  505 
ADL; Katz Basic Activities of Daily living scale, AES; Apathy Evaluation Scale, BADS; Behavioural Activation for Depression Scale, BATD; Brief Behavioural Activation 506 
Treatment for Depression, BDI; Beck Depression Inventory, BI; Barthel Index, CMAI; Cohen -Mansfield Agitation Inventory-Long form, BT-PE; Behavioural therapy 507 
pleasant events, BT-PS; Behavioural therapy problem-solving, CSDD; Cornell Scale for Depression in Dementia, CSI; Carer Strain Index, DRS; Dementia Rating Scale, 508 
DSM-III; Diagnostic and Statistical Manual of Mental Disorders-III, EROS; Environmental Reward Observation Scale, FAST; Frenchay Aphasia Screening Test, GDS; 509 
Geriatric Depression Scale, HDRS; Hamilton Depression Rating Scale, HSCL-20; Hopkins Symptom Checklist – 20, MAS; The motivation assessment scale, MMSE; Mini–510 
Mental State Examination, NIHSS; National Institutes of Health Stroke Scale score, NLQ; Nottingham Leisure Questionnaire, PDQ-39; Parkinson’s Disease Quality of Life, 511 
PEARLS; Program to Encourage active, Rewarding Lives for Senior, PES; The pleasant events schedule, PHQ9; Patient Health Questionnaire-9, QOL-AD; Quality of life -512 
Alzheimer's disease, QOLIE-31; Quality of life in Epilepsy – 31, RAISD; Reinforcer assessment for individuals with severe disabilities, RIL; Record of Independent Living, 513 
SADQH-10; Stroke Aphasic Depression Questionnaire Hospitals-10 item, SADQH-21; Stroke Aphasic Depression Questionnaire Hospitals-21 item, SIS; Stroke Impact 514 
Scale, SST; Sheffield Screening Test, UPDRS; Unified Parkinson's Disease Rating Scale, VASES; Visual Analogue Self-Esteem Scale, ZBI; Zarit Burden Inventory.  515 
Table 2 516 
Methodological characteristics of studies 517 
Study Clear 
statement of 
aims 
Participant 
demographics  
Sample 
representativeness 
(n)  
Inclusion and 
exclusion criteria  
Standardised 
measures  
Attrition Randomisation Blinding  Treatment 
fidelity 
Additional sources of 
bias 
Feliciano, Steers 
31
 
Yes Moderate No (n=11), 
participants with 
depression (n=4) 
No Yes Yes N/A N/A No Selection bias 
Reporting bias 
Confounders 
Teri, Logsdon 23  Yes Yes Yes (n =72) Yes Yes Yes Moderate Yes No Confounders 
Travers 25 Yes Yes No (n =18) Yes Moderate Yes Yes No No Selection bias 
Detection bias 
Performance bias 
Teri and 
Uomoto 32 
Yes No No (n =4) No Yes No N/A N/A No Selection bias 
Detection bias 
Confounders 
Thomas, Walker 
24
 
Yes Yes Yes (n =105) Yes Yes Yes Yes Moderate Yes  
Kirkness, Cain 
27 
Yes Yes Moderate (n =100) Moderate Yes Yes Yes Yes Moderate Reporting bias 
Concurrent 
intervention 
Mitchell, Veith 
28 
Yes Yes Yes (n =101) Moderate Yes Yes Yes Yes No Change scores 
calculated rather than 
absolute difference 
between groups 
Ciechanowski, 
Chaytor 26  
Yes Yes Yes (n =80) Moderate Moderate Yes Yes Yes Moderate   
Butterfield, 
Cimino 30  
Yes Moderate Moderate (n =34) Moderate Yes Yes N/A N/A Yes  
Hart, Vaccaro 29 Yes Yes Yes (n = 65) Yes Yes Yes Yes Yes Moderate  
 Note. Table collates Critical Appraisal Skills Programme tools for a single point of reference   
  518 
Figure 1. PRISMA Flow Diagram 519 
  520 
Records identified through 
database searching 
(n = 2696) 
Sc
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g 
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Id
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o
n
 
Additional records identified 
through other sources 
(n = 18) 
Records after duplicates removed 
(n = 1829) 
Records screened by title 
and abstract  
(n = 1829) 
Records excluded 
(n = 1780) 
Full-text articles assessed 
for eligibility 
(n = 49) 
Full-text articles excluded, 
with reasons 
(n =39) 
21 not behavioural 
activation 
11 non-neurological 
population 
1 dissertation 
2 reviews 
1 protocol 
2 subsidiary paper 
1 18-month follow up 
  
References of full-text 
articles’ assessed (n=662) 
Studies included in the 
review 
(n = 10) 
Appendices 521 
Appendix A. Example search strategy for PsycINFO 522 
1 neurological conditions 
2 neurological disorders 
3 neurological illness 
4 brain injury 
5 Dementia 
6 alzheimer* 
7 multiple sclerosis or ms 
8 huntington* 
9 stroke 
10 parkinson* 
11 ataxia 
12 dystonia 
13 motor neurone disease or als or mnd or amyotrophic lateral sclerosis 
14 chronic fatigue syndrome or myalgic encephalomyelitis 
15 muscular dystrophy 
16 progressive supranuclear palsy 
17 transverse myelitis 
18 spinal injury 
19 meningitis 
20 epilepsy 
21 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 
OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 
22 (MH "Depression") 
23 depression 
24 low mood 
25 dysthymia 
26 depressive 
27 depressed 
28 depressive disorder 
29 S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 
30 behavio* activation 
31 behavio* therapy 
32 activity schedul* 
33 positive reinforce* 
34 event schedul* 
35 behavio* treatment 
36 behavio* intervention 
37 behavio* therap* 
38 behavio* activat* 
39 behavio* modif* 
40 behavio* psychotherap* 
41 S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR 
S39 OR S40 
42 S21 AND S29 AND S41 
  523 
Appendix B. Data extraction template headings 524 
 525 
Data were extracted using the following headings: (a) study identifiers: title, authors, 526 
date, country/location, (b) study characteristics: methodology, sample size, aims, design, 527 
inclusion/exclusion criteria, recruitment method, randomised-controlled trials details, 528 
incomplete data, attrition, bias, (c) participants’: age, gender, depression scores, ethnicity, 529 
primary and secondary health condition, (d) intervention: delivery format, intervention 530 
facilitator, individual/group, session duration, number of sessions, intervention setting, 531 
behavioural activation manual, fidelity checks, adaptations, comparator/control, (e) outcome 532 
measures: primary measure, quality of measure, secondary measure, quality of secondary 533 
measure, duration assessed/follow up, (f) analysis: quantitative/qualitative, tests used, 534 
missing data reported, and (g) results/findings: primary, secondary, comparator/control, 535 
themes, comments, and effects on neurological condition reported.  536 
 537 
